当前位置：
X-MOL 学术
›
Aliment. Pharm. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Editorial: infliximab or adalimumab as first- or second-line anti-TNF—conflicting evidence—authors' reply
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-08-23 , DOI: 10.1111/apt.16569 Isabella Visuri 1 , Carl Eriksson 1, 2 , Ola Olén 2 , Yang Cao 1 , Emelie Mårdberg 1 , Olof Grip 3 , Anders Gustavsson 4 , Henrik Hjortswang 5 , Pontus Karling 6 , Scott Montgomery 1, 2 , Pär Myrelid 5 , Jonas F Ludvigsson 1, 2 , Jonas Halfvarson 1
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-08-23 , DOI: 10.1111/apt.16569 Isabella Visuri 1 , Carl Eriksson 1, 2 , Ola Olén 2 , Yang Cao 1 , Emelie Mårdberg 1 , Olof Grip 3 , Anders Gustavsson 4 , Henrik Hjortswang 5 , Pontus Karling 6 , Scott Montgomery 1, 2 , Pär Myrelid 5 , Jonas F Ludvigsson 1, 2 , Jonas Halfvarson 1
Affiliation
This article is linked to Visuri et al and Haydek & Scott papers. To view these articles, visit https://doi.org/10.1111/apt.16525 and https://doi.org/10.1111/apt.16555
中文翻译：
社论：英夫利昔单抗或阿达木单抗作为一线或二线抗 TNF——相互矛盾的证据——作者的答复
本文链接到 Visuri 等人和 Haydek & Scott 的论文。要查看这些文章，请访问 https://doi.org/10.1111/apt.16525 和 https://doi.org/10.1111/apt.16555
更新日期：2021-08-24
中文翻译：
社论：英夫利昔单抗或阿达木单抗作为一线或二线抗 TNF——相互矛盾的证据——作者的答复
本文链接到 Visuri 等人和 Haydek & Scott 的论文。要查看这些文章，请访问 https://doi.org/10.1111/apt.16525 和 https://doi.org/10.1111/apt.16555
京公网安备 11010802027423号